Award Number: DAMD17-01-1-0193

TITLE: Soy and Tamoxifen for Breast Cancer Prevention in High

Risk Pre-Menopausal Women

PRINCIPAL INVESTIGATOR: Jeffrey A. Tice, M.D.

CONTRACTING ORGANIZATION: University of California, San Francisco

San Francisco, California 94143-0962

REPORT DATE: October 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and

suggestions for reducing this burden to Washingto to the Office of Management and Budget, Paperw 1. AGENCY USE ONLY (Leave	ork Reduction Project (0704-0188), Washing	ton, DC 20503	ID DATES COVERED	
1. AGENCY USE ONLY (Leave	October 2002	0	p 01 - 16 Sep	02)
4. TITLE AND SUBTITLE	TOCCOBEL 2002	THIRD (17 DC	5. FUNDING NUME	
Soy and Tamoxifen for	Breast Cancer Prever	tion in High	DAMD17-01-1-	0193
Risk Pre-Menopausal Wo				
•				
6. AUTHOR(S)			1	
Jeffrey A. Tice, M.D.				
- personalis openius	MANE(O) AND ADDDEOC/EO)		8. PERFORMING O	IDC ANIZATION
7. PERFORMING ORGANIZATION I	NAME(S) AND ADDRESS(ES)		REPORT NUMBE	
University of Californ	ia San Francisco		III. OIII IIOIIIDI	
San Francisco, Californ	•			•
San Francisco, Carrior	111a 94143-0902			
E-Mail: jtice@medicin	e nest edn	9		
B-Marr. Jerceemedieri	ie. desi. edu	Ĺ.	•	
9. SPONSORING / MONITORING A	GENCY NAME(S) AND ADDRES	SS(ES)	10. SPONSORING	MONITORING
	\	•	AGENCY REPO	ORT NUMBER
U.S. Army Medical Rese	earch and Materiel Co	ommand .		
Fort Detrick, Maryland	l 21702-5012			
	•		• *	•
·				
11. SUPPLEMENTARY NOTES				
			•	
12a. DISTRIBUTION / AVAILABILIT	VETATEMENT		1 10	2b. DISTRIBUTION CODE
12a. DISTRIBUTION / AVAILABILIT	TSIAIEWENI	•	' '4	D. DISTRIBUTION CODE
Approved for Public Re	elease: Distribution	Unlimited	÷	
			,	
	•			4
I		· ·	· 1	

13. ABSTRACT (Maximum 200 Words)

The current study will test the feasibility and preliminary efficacy of soy supplementation to decrease risk of breast cancer by reducing breast density in individuals with >50% breast density on mammography and who are at elevated risk for breast cancer. Tamoxifen, the only prophylactic agent known to be effective for breast cancer, will be used as a positive control to validate the use of the proposed surrogate markers including breast density. A randomized placebo controlled design will allow for comparative toxicity and efficacy determinations using patients symptoms scores and validated quality of life tools. Biological endpoints of mammographic breast density, breast cytology, urinary estrogen metabolites, and blood serum biomarkers (IGF-1/IGF-BP 3) will be validated using tamoxifen compared with placebo. The magnitude of the soy effect on the same markers will then be compared with that of tamoxifen. Feasibility will be assessed by measuring the rate of recruitment, the percentage of women consuming at least 80% of the expected number of protein packets, and the dropout rate. Initial participant screening has just begun and clinic visits are expected to start in October 2002. At this date there is no data or results to report.

14. SUBJECT TERMS soy isoflavones, breas density, quality of li	st cancer prevention, m	ammographic breast	15. NUMBER OF PAGES 57 16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102

Table of Contents

Cover	l
SF 298	
Introduction	1
Introduction	· · · · · · · · · · · ·
Body	1
Key Research Accomplishments	3
Reportable Outcomes	4
Conclusions	4
Appendices	

Introduction

The PREVENT study is testing the feasibility and preliminary efficacy of soy supplementation to decrease risk of breast cancer in women with >50% breast density on mammography who are at elevated risk for breast cancer using the Gail model. Tamoxifen, the only prophylactic agent known to be effective for breast cancer, is being used as a positive control to validate the use of the proposed surrogate markers including change in breast density. The randomized placebo controlled design allows for comparative toxicity and efficacy determinations using patient symptom scores, validated quality of life tools, and adverse event profiles. Biological endpoints including changes in mammographic breast density, breast cytology, urinary estrogen metabolites, and blood serum biomarkers (IGF-1/IGF-BP 3, hormone levels) are being validated using tamoxifen compared with placebo.

Accomplishments, Challenges and Future Goals

The framework for successful completion of the study has been put into place in the last year. Forms for collecting data related to all aspects of the study have been designed, tested, and printed (appendix A). A computerized system with optical character recognition has been set up to facilitate data entry and validation. A software data verification system with extensive edits for range checks, missing data, and logical inconsistencies have also been designed and tested. Standard operating procedures have been established for the involvement of numerous working groups at UCSF such as the Breast Care Center (BCC), mammography, radiology, phlebotomy and research lab staff. As recently as one month ago, the final approval was obtained from the local Clinical Human Research committee (CHR) for the study protocol, informed consent, study brochure, as well as several informational tools (appendix B) that will be provided to participants during the intervention period.

The start of the study has been delayed in the past year due to complications relating to contract negotiations and agreement on details of the study protocol between the multiple agencies involved in the management and support of the project. The establishment of a contract with AstraZeneca, the manufacturer of tamoxifen, was delayed, but mutually agreeable terms were reached and both tamoxifen and identical placebo have been received and packaged by our research pharmacy. The approval of

the study protocol by the DOD required months of correspondence before a version that met the local IRB requirements, as well as the DOD, was achieved. The inclusion of Dual X-Ray Absorpotometry (DXA) measurements in the protocol was approved by the local IRB but was an area of concern for the DOD, which resulted in the approval being delayed a little over 1 month. The wording of the *Treatment and Compensation* clause in the informed consent which the local IRB requires specific wording was not acceptable to the DOD and resulted in an additional delay of a final approval several months. The delays encountered with the DOD Office of Regulatory Compliance and Quality can be attributed partially to the departure of the Human Subject Protection Specialist assigned to our protocol and the lag time before contact was made with the new specialist. At the present time approval from the local IRB has been obtained and we are waiting for the DOD approval to be finalized by the DOD contract specialist.

A relative hands off approach by the study coordinator proved to be ineffective in moving forward the project, which involves several parties with varying interests. These challenges have been overcome by active involvement of a new project manager in facilitating the movement of the project forward. We foresee challenges in patient recruitment in the upcoming year, but plan to overcome them by using a recruitment strategy that includes a combination of community outreach events, involvement of practitioners in related fields and advertising in the local print media. In addition, representatives of the study have attended community outreach events aimed toward the local at risk population. The study is also in the process of coordinating with professionals at San Francisco General Hospital in order to offer study participation to women of varied economic and ethnic backgrounds.

The goals for the future are focused around the implementation of the study and enrolling approximately 75% of our final accrual goal of 200 participants by the end of 2003. In the short term, our goal is to enroll 10 participants by January of 2003. Recruitment will then be expanded in the coming year from the established BCC Prevention program patients to women of the greater San Francisco Bay area and the goal will be to enroll 9 women a month into the trial during the 2003 year.

Preliminary screening of women through the UCSF BCC Prevention program has revealed that the current inclusion/exclusion criteria in relation to the assessment of breast cancer risk will prove to be a challenge in finding enough eligible women. In order to overcome this challenge we plan to expand the inclusion criteria to

women with a family history of breast cancer that includes second-degree relatives, rather than the current model that only includes first-degree relatives. A modification is being prepared and will be submitted to the DOD and local CHR by the end of October 2002.

If accrual goals are not consistently met in the early part of 2003, inclusion criteria will be broadened to include women with at least one cancer free breast. The addition of these women to the study population will require a complex set of modifications to the study protocol. The study coordinator, with the supervision of the primary investigators, will investigate these issues over the next few months in order to be prepared if these modifications are required.

Key Research Accomplishments

- UCSF IRB approval of protocol 11/28/2001
- Development of new software for determining breast density
- Training of a radiologist in use of new procedure for determining breast density
- Validation of breast density analysis procedure using 144 sample images with percentage breast density ranging form 0% to 100%.
- Optimization of breast density analysis procedure for use with a G.E. digital mammography instrument, which will be used for all study mammograms
- Designed, tested and printed forms for data collection related to all aspects of the study (appendix A)
- Establishment of a computerized optical character recognition system for data entry and validation
- Development of standard procedures for the collection of biological specimens, including blood, urine and breast duct fluid
- Development of standard procedures for the transport, labeling and storage of biological specimens
- Establishment of contacts with practitioners outside of the UCSF group for referrals of eligible patients
- Development of informational tools to assist participants in following the approved protocol (appendix B)
- Development of procedures for the storage and dispensation of the study drugs with the research pharmacist, Monica Lee, PharmD.

- Soy protein powder and identical placebo received for Protein Technologies International, packaged and labeled by UCSF Cancer Center research pharmacy
- Tamoxifen and identical placebo received from AstraZeneca, packaged and labeled by UCSF Cancer Center research pharmacy

Reportable Outcomes

There are no reportable outcomes at the time of this report. A description of the activities performed over the last year and plans for the completion of the research goals in the upcoming year can be found in an earlier section of this report

Conclusions

All aspects involved in the implementation of the approved study protocol are in place and will be implemented once final approval is received from the DOD.

Appendix A


Study Forms




Screening ID#	Acrostic		Date of Inter	view	Staff ID#
		Month /	Day	Year	0 0

INITIAL SCREENING INTERVIEW


Participant Statu																		
O E	Eligible,	scre	enin	ıg vi	isit	sche	edul	ed										
O E	Eligible,	but r	not i	nter	est	ed o	r re	fuse	ed to) sc	hed	ule :	scre	eni	ng v	/isit		
01	Not elig	jible																
O.F	Refuse	d to c	omp	olete	e sc	reer	ning	inte	ervie	:W								
0(Call bad	ck, wł	není	?	•	_	•	D	ate:		fonth.	- /		 ay	1 -	Yea	 .r	
								T	īme:		- vanna	-:		· -	C	am pm	l	
First I would like to	o confi	rm so	me i	nfor	mai	tion	abo	ut y	ou:									
irst Name				<u> </u>	!		<u> </u>	·		L	<u></u>	1	L	<u> </u>	L	<u>. </u>	<u>l. </u>	
Last Name Home Address	· T T	Ī	<u> </u>	T	<u> </u>		I		<u> </u>	, 		<u> </u>		<u>'</u>			TT	
Street Address				<u> </u>		<u> </u>	<u> </u>	<u> </u>	<u> </u>		<u> </u>	<u> </u>			<u></u>			
Apt/Room]													
		,	Ī				Π	T .					<u> </u>	T	Τ	Γ	1 [T
 	<u> </u>		<u> </u>	<u> </u>	<u> </u>			1	<u> </u>	<u> </u>	<u>. </u>		<u> </u>		<u> </u>	<u> </u>	J L s	tat
Zip Code	_ [•											
· Home Telephone:								٧	Vork	Tel	epho	ne:						
	ТТ				Τ	Τ	7	7		T		١Γ	T		\neg	_ [Τ



Page 2 of 7



Interviewer Note: This includes women who are currently pregnant.





Page Link#

Screening ID # Acrost	tic	Date of Int	erview	Staff ID#
] / 🔲 /	/	

		T T	INITIAL	SCREENI	NG IN	TERVIEW	
13.	Have y	ou <u>ever</u> bee	en pregnant?				
·	_	O Yes	O No	O Don't know		O Refused	
			w many of your terviewer Note:			ne birth of a live child 15.)	?
				pregnancies	O Don't	know	
		13b. Ho	w old were you	when your first c	hild was l	oorn?	
		:		years old	O Don't	know	
14.	In the	past 6 mo	nths, have you b	reast-fed a child	J?		
		O Yes	O No	O Don't know	,	O Refused	
			INELIGIBLE.	Go to Question #	[!] 2 5.		
15.	What	is your ethn O Asi	ic background? ian		O Native	e American	
			ick/African Amer	ican		/Caucasian	
	٦		waiian/ Other Pa				
			spanic or Latino	ionic islanuel	O Refus	(Please specify:	
16.	Was vo	ur natural	mother (the one	that gave birth	to you)	ever diagnosed with	hreast cancer?
	, , , ,	O Yes	O No	O Don't know		O Refused	<u>breast caricer</u> !
17.	Do y	ou have ar	ny living and/or	deceased FULL	SISTER	RS (same mother an	d father as you)?
٠		O Yes	O No	O Don't know	w	O Refused	
			Go	to Question #18.			·
	17	a. Have a	ny of your FULI	_ SISTERS <u>eve</u>	<u>er</u> been di	iagnosed with <u>breas</u>	t cancer?
			O Yes	O No	90	Oon't know	
		٠.		Go to Question	#18.		
	·	i.) How	many of your F	ULL SISTERS	had brea	ast cancer?	
			full sister	rs	0 [Oon't know	


Page 4 of 7 PREVENT-Initial Screening Interview 06/20/02




Screening ID#	Acrostic	Date of Interview	Staff ID#

INITIAL SCREENING INTERVIEW


18. Do you have any living and/or deceased DAUGHTERS? (Do NOT include step-daughters or daughters who are not blood relatives.)



19. Has a doctor ever told you that you have deep vein thrombosis (DVT) or blood clots?




20. Has a doctor ever told you that you have irritable bowel syndrome (IBS)?



INELIGIBLE. Go to Question # 25.

Page 5 of 7

Page Link#





Screening ID#	Acrostic	Date of Interview	Staff ID#
		//	

INITIAL SCREENING INTERVIEW

~ -	_	·	_			
<i>Z</i> 3	. /	Interviewer	Note:	Do	not	read

Is the participant eligible to continue screening for the study?

O Yes

O No

INTERVIEWER NOTE: IF SCREENEE IS <u>ELIGIBLE</u> READ THE FOLLOWING SCRIPT

Thank you for your answers. From the information you have just given me, it is very likely that you are eligible to participate in this study. The next step is for us to schedule a time for you to come to the clinic for an exam. We will be performing a series of tests and asking you some more detailed medical history questions at your screening visit, to ensure that you are eligible. This clinic visit may take up to 3 hours. This visit needs to take place during days 7-13 of your menstrual cycle.

What date and time of the day is most convenient for you? (Check available dates and times.)

I will call you back to schedule the appointment with you.

Do you have any questions? Please feel free to call me at () _____ if any questions should come up.

That's about all the information I need at this time. I'd like to thank you for taking the time to talk to me. I look forward to meeting with you.

INTERVIEWER NOTE: IF SCREENEE IS INELIGIBLE READ THE FOLLOWING SCRIPT

Thank you very much for this information. It will be very useful in the study. Only a limited number of people are being selected to come to the clinical part of the study. At this time you are not eligible to participate in the study, but we greatly appreciate your time and effort in answering questions for us.


I would like to thank you for taking the time to talk to me. If you have any questions, please feel free to call me at ()_____.

Interviewer Note: Go to Page 1 and complete the Participant Status section.

Page Link#











Screening ID#	Acrostic	Date of	Interview	Staff ID#
		Month Day	/ Year	

SCREENING VISIT CHECKLIST

	Plea	ase check if co		
Checklist Items	Yes	No, participant refused	No, other reason	Comments
1. Informed consent	0	0	0	
2. Medical History	0	0	0	
3. Menstrual History	0	0	0	
4. Anthropometrics	0	0	0	
5. Vital Signs	0	0	0	
6. Physical Exam	0	0	0	
7. Blood Draw	0	0	0	
8. Mammogram	0	0	0	
9. Dispense Run-in	0	0	0	

Participant Status

- O Eligible to continue, randomization visit scheduled
- O Eligible, but not interested or refused to schedule randomization visit
- O Not eligible
- O Not eligible, refused screening visit interview



Screening ID #	Acrostic	Date of	Interview	Staff ID#
		Month Day	/ Year	

MEDICAL HISTORY

Past Medical History

Please indicate any significant illnesses which apply to participant:

							-
1.	Angina (chest pain)	O Yes	O No	8.	Deep vein thrombosis	O Yes	O No
2.	Atrial fibrillation	O Yes	O No	9.	Transient ischemic attack (TIA)	O Yes	O No
3.	Heart attack	O Yes	O No	10.	Depression	O Yes	O No
4.	Heart failure	O Yes	O No	11.	Nervous or emotional disorder	O Yes	O No
5.	High blood pressure (hypertension)	O Yes	O No	12.	Psychiatric problems	O Yes	O No
5a.	If YES, is the hypertensic currently controlled?	on O Yes	O No	13.	Liver disease, yellow jaundice, hepatitis, cirrhosis	O Yes	O No
6.	Stroke	O Yes	O No	14.	Superficial phlebitis	O Yes	O No
7.	Pulmonary embolism	O Yes	O No				
15	Other major illnesses (please describe):						
					,		



Screening ID#	Acrostic	Date of	Interview:	Staff ID#
		Month Da	y / Year	

MEDICAL HISTORY (cont.)

Medication History

Please indicate below which of the medications the participant is currently taking or has taken. If the participant has never taken the medication, select both "No" bubbles. If the participant has ever taken the medication in the past, select the appropriate "Yes" bubble. For "Yes" answers, please record the date of the last dose.

	Medications	Currently Taking	Previously Taken	Date Last Taken
16.	Antidepressants (Prozac, Elavil, etc.)	OYes ON	O Yes O No	
17.	Antiestrogen (Tamoxifen, etc.)	O Yes O No	O Yes O No	
17a.	If "YES", what was the duration of therapy		months	
18.	Selective estrogen receptor modulator (Raloxifene)	O Yes O No	O Yes O No	
¹ 8a.	If "YES", what was the duration of therapy		months	
19.	Blood thinners (Coumadin, Dicumarol, etc.)	O Yes O No	O Yes O No	
20.	Diethylstibestol	OYes ON	O Yes O No	
21.	Estrogen (oral estrogen or vaginal creams)	O Yes O No	O Yes O No	
22.	Oral contraceptives (birth control pills)	O Yes O No	O Yes O No	
23.	Progesterone	O Yes O No	O Yes O No	
24.	Other hormone, specify	O Yes O No	O Yes O No	
25.	Investigational drug(s)	O Yes O No	O Yes O No	
	(please specify):			
				1100,000
	· · · · · · · · · · · · · · · · · · ·			· · · · · · · · · · · · · · · · · · ·
			.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	



Screening ID #	Acrostic	Date of Interview	Staff ID#
		Month Day Year	

SMOKING AND ALCOHOL HISTORY

Smoking	/Alcohol	History:
----------------	----------	----------

26. Have you smoked at least 100 cigarettes (5 packs) in your entire life?

	O Yes ▼	O No —▶ Skip to Question #30.	
27. Ho	w old were you when you first star	ted smoking regularly? years old.	
28. On cig.	the average of the entire time you arettes did you smoke per day?	smoked, how many cigarettes	
29. Do	you smoke cigarettes now? Organization	P No	
	About how many cigarettes do you smoke per day?	How old were you when you stopped smoking?	
	cigarettes	years old	

30. Have you ever, or do you currently drink alcohol?

O Yes, but only in the past

O Yes, currently

O No, never

30a. If yes, on average, how many alcoholic beverages (i.e. beer, wine, mixed drinks, etc.) do you currently consume weekly?

O None

O Less than 1 drink per week

O 1-4 drinks per week

O 5-9 drinks per weeks

O 10-19 drinks per week

Page 3 of 4

O more than 19 drinks per week

Page Link #

PREVENT-Medical History 03/05/02

Draft





Screening ID#	Acrostic	Date of Interview	Staff ID#
		Month Day / Year	

CONTACT INFORMATION

31.	Ple	ase	prov	vide	the	nar	ne a	and a	addı	ress	of o	one	pers	on	who	car	ı alv	vays	rea	ch y	you.				
	First	t Nan	ne							····											L				
						•	 																		
	Last	Nam	ne							.		····	<u> </u>	\ <u></u>				L			L				
	Stre	et Ad	ldress				1			,							·		<u></u>	• •		<u> </u>			
																						,		1.	
	Apt	/Roor	n																						1 · · · · · · · · · · · · · · · · · · ·
	1.																								
	City	,	,		,	•						•					·		·	.	·		,	State	<u> </u>
						-																			
	Zip	Code	:								-														
	Hor	ne Te	lepho	ne:				_						V	ork '	Геlер	hone:	:							
()				-						() [-			
	Are	a Coo	ie					Nu	mber				-		A	rea C	ode					N	lumb	er	

Page 4 of 4



Screening ID#	Acrostic	Date of Interview	Staff ID#
		Month Day Year	

MENSTRUAL HISTORY

1.	In the <u>past 6 months</u> , have you had regular menstrual periods (do NOT include bleeding due to taking female hormone pills)?
	O Yes O No O Don't know O Refused
2.	Date of onset of last menstrual period?
3.	How old were you at the time of your first menstrual period? If you are unsure, please make your best guess. years old O Don't know O Refused
4.	Now please think about the past 3 months. In the past three months, have you used any oral contraceptives (birth control pills) for any reason, such as contraception, acne, menstrual irregularities, etc.)? O Yes O No O Don't know O Refused
5.	Have you ever had a hysterectomy (surgery to remove your uterus or womb)? O Yes O No O Don't know O Refused 5a. If you had a hysterectomy, how old were you when you had this surgery? years old
6.	Have you ever had an oophorectomy (removal of an ovary)? O Yes O No O Don't know O Refused 6a. If you had an oophorectomy, what was the type? O Unilateral O Bilateral O Unknown
	6b. If you had an ophorectomy, what was the date? Month Year



Screening ID#	Acrostic	Da	te of Interview	gyan verencera. Posta	Staff ID#
		Month /		Year	

ANTHROPOMETRY

Visit:	O Screening Visit O 6 Mo	onth Visit (Closeout)	
STANDING HEIGHT	cm		Staff ID#:
WEIGHT	kg		Staff ID#:



Screening ID#	Acrostic		Date of Inten	view	Staff ID#
		Month /	Day /	Year	

VITAL SIGNS

BLOOD PRESSURE	t: O Screening Visit O 6 Month Visit (
		Staff ID#
a. Cuff Size	O Small O Regular O Large	
b. Arm Used	O Right O Left	
*Examiner Note: If po	ssible, use same arm as in previous visit	
BLOOD PRESSUF Sitting Blood Pressur c. Systolic		
d. Diastolic	mmHg	
RADIAL PULSE		Staff ID#
	beats per minute	



		A second control of the control of t		1
Screening ID #	Acrostic	Date of Inten	riew	Staff ID#
		Month Day	Year	

PHYSICAL EXAMINATION

	O Screening Visit	O 6 Month Visit (Closeout)
1. Examinations		Describe Abnormalities
Eyes, Ears, Nose, Throat	O Normal O Abnormal O Not done	
Head, Neck (including thyroid)	O Normal O Abnormal O Not done	
Heart	O Normal O Abnormal O Not done	
Lungs	O Normal O Abnormal O Not done	
Abdomen (liver, kidney, spleen, gastrointestinal)	O Normal O Abnormal O Not done	
Lymph Nodes	O Normal O Abnormal O Not done	
Skin	O Normal O Abnormal O Not done	
Musculoskeletal (extremities/spine)	O Normal O Abnormal O Not done	
Neurological	O Normal O Abnormal O Not done	
General appearance	O Normal O Abnormal O Not done	
Pelvic	O Normal O Abnormal O Not done	
Breast Exam Score: I-involutional II=fibrocystic	O I O II	O O V O V m 3-6 mos or sono IV=suspicious;needs bx V=frank cancer

If abnormal findings are clinically significant (at PI's discretion), fill out the Adverse Events form and refer for appropriate follow-up treatment.



Screening ID#	Acrostic		Date of Intervi	eW «	Staff ID#
		Month /	Day /	Year	

BLOOD DRAW

Visit: O Screening Visit

O 6 Month Visit (Close Out)

1. Was any blood drawn?

O Yes

Q No

Please describe why not?

2. Were tubes filled to specified capacity? If not, comment why.

	<u>Vol.</u>	<u>YES</u>	<u>NO</u>	
1. Serum	10 ml	0	$\overset{\circ}{\longrightarrow}$	
2. Serum	10 ml	Ö	\hookrightarrow	
3. Serum	10 ml	0	$\circ \rightarrow$	
4. EDTA Plasma	10 ml	0	$\circ \rightarrow$	
5. SST	10 ml	0	$\circ \rightarrow$	
6. SST	10 ml	0	$\circ \rightarrow$	
7. SST	10 ml	0	$\circ \rightarrow$	



Screening ID#	Acrostic		Date of Inter	view	Staff ID#
		Month /	Day /	Year	

STUDY DRUG PLACEBO DISPENSATION for RUN-IN

1.	A one month's supply (35 packages) of soy/placebo has been dispensed to participant?	O Yes O No
2.	Soy/Placebo Package #:	
3.	A one month's supply of tamoxifen/placebo (35 pills) have been dispensed to participant?	O Yes O No
4.	Tamoxifen/Placebo Pill Bottle #:	
5.	Was the 24 hour urine collection kit dispensed?	O Yes O No



Screening ID#	Acrostic	Date	of Interview	ight.	Staff ID#
		Month D	ay Year		

RANDOMIZATION VISIT CHECKLIST

NOTE: This visit must take place only on days 7-12 of the patient's menstrual cycle.

	Please check if completed				
Checklist Items	Yes	No, participant refused	No, other reason or N/A	Comments	
1. Run-in Compliance	0	0	0		
2. Medication Inventory	0	0	0		
3. Symptom Checklist	0	0	0		
4. CES-D	0	0	0		
5. 24 Hour Urine	0	0	0		
6. Nipple Aspiration Lavage	0	0	0		
7. Final Eligibility	0	0	0		
8. Randomization	0	0	0		

Participant Status

- O Eligible to continue, randomize and dispense pills/packets
- O Eligible, but not interested
- O Not eligible



Screening ID #	Acrostic	Date	of Interview	Z Ž	Staff ID#
		Month Da	y Year		

RUN-IN COMPLIANCE

	KOIV-IIV		INCE					
Note: The participant	should take today's	dosage befor	e this form is complete	ed.				
Date of Screening	g Visit:	Month	Day Year					
Number of days s	since Screening Visit	:						
Number of tablets rema	aining:	Number of pa	ackets remaining:					
nd the row corresponding blets that the participant h w in the table, then they a	nas left is less than e re eligible for rando	or equal to the mization (con	e number in the corres npliance > 80%).	sponding				
Days Since Screening Visit	Maximum Nu of Tablets Rer	•	Maximum Number of Packets Remaining					
25	20	namig	20	ing				
26	21		21					
27	22		22					
28	23		23					
29	23		23					
30	24		24					
31	25	·	25					
32	26		26					
33	26		26					
34	27		27					
35	28		28					
Eligibility:			·					
≥80% compliance tablets	O Yes O No	≥ 80% compli	ance packets OYes	Q No				
	Ineligible		· [neligible				



Screening ID#	Acrostic		Date of Intervi	ew	Staff ID#
		Month /	Day /	Year	

MEDICATION INVENTORY

Please record r	nedication	ons th	e part	icipa	ant is cu	rrent	ly tal	king i	nclu	ding	ove	er th	e cou	ınter	me	dicat	ions.
A. Medication																	
Date Started	Month	/ Da	y	/ [Year											٠.	
B. Medication																	
Date Started	Month	/ Da	ly	/ [Year												
C. Medication																	
) Date Started	Month	/ Da	у	/ [Year												
D. Medication																	
Date Started	Month	/ D	ay	/ [Year												
E. Medication																	·
Date Started	Month	/	ay	/[Year												
F. Medication																	
Date Started	Month	/	ay	/[Year				-								

Page Link #

PREVENT-Medication Inventory 03/05/02

Drait




Screening ID#	Acrostic	Date of Interview	Staff ID#

MEDICATION INVENTORY (cont'd)

Please record medications the participant is currently taking including over the counter medications.																	
G. Medication																	
Date Started	Month	/	Day		/-[Ye	ar				s 1						
H. Medication																	
Date Started	Month	/	Day	у	/[Ye	ar										
I. Medication																	
Date Started	Month	/	Day	y	/[Ye	ar					,					
J. Medication																	
Date Started	Month	/	Da	ay	/[Y	ear		٠							,	-
K. Medication																	
Date Started	Month] /			/[Ye	ear			•		,					
	MOHILI		Da	ıy			zai										
L. Medication				ly													







	P
122	R
7	R E
1 /2	V
	E
	N
	T

Screening ID #	Acrostic		Date of Inter	view	Staff ID#
		Month /	Day /	Year	

SYMPTOM CHECKLIST

Visit:	O Randomization	O 3 Month Visit	O 6 Month Visit ((Closeout)
--------	-----------------	-----------------	-------------------	------------

Dear Participant: Please fill out this form and return it to a PREVENT staff member. If you have any questions about how to answer the items on this form, please ask for help. All of the information collected on this form will be kept strictly confidential and will be used only for research purposes. If you feel uncomfortable about answering any of these questions, please leave the item blank. Your answers to these questions will not affect your continued participation in this study.

What was the date of the first day of your last menstrual period?		'	/
	Month	Day	Year

We are interested in knowing the extent to which you have been bothered by any of the following problems during the <u>PAST FOUR WEEKS</u>. Please SELECT the appropriate number, using the following code:

0 - Not at all 1 - Slightly 2 - Moderately 3 - Quite a bit 4 - Extremely

<u>)</u>		you	ı be		oth	ive ered eks?	·	How much you been be in the past 4							
	Symptom Problem	0	1	2	3	4			Symptom Problem	. 0	1	2	3	4	
1.	Hot flashes	0	0	0	0	0		11.	Weight loss	0	0	0	0	0	
2.	Night sweats	0	0	0	0	0		12.	Decreased appetite	0	0	0	0	0	
3.	Cold sweats	0	0	0	0	0		13.	Abdominal cramps	0	0	0	0	0	
4.	Constipation	0	0	0	0	0		14.	Leg cramps	0	0	0	0	0	
5.	Vaginal discharge	0	0	0	0	0		15.	Difficulty with bladder control (when laughing or crying)	0	0	0	0	0	
6.	Vaginal bleeding or spotting	0	0	0	0	0		16.	Difficulty with bladder control (at other times)	0	0	0	0	0	
7.	Genital itching/irritation	0	0	0	0	0		17.	Weight gain	0	0	0	0	0	
8.	Vaginal dryness	0	0	0	0	0		18.	Forgetfuliness	0	0	0	0	0	
9.	Pain with intercourse	0	0	0	0	0		19.	I felt that people disliked me.	0	0	0	0	0	
10.	Dry mouth	0	0	0	0	0		20.	I could not get going.	0	0	0	0	0	
	,			•		<u> </u>						·		<u>. </u>	
Signature of Person Completing Form											orm				

Page 1 of 2

Page Link #

PREVENT-Symptom Checklist 03/05/02







The first control of the first		
Screening ID# Acrostic	Date of Interview	Staff ID#

SYMPTOM CHECKLIST (cont'd)

We are interested in knowing the extent to which you have been bothered by any of the following problems during the <u>PAST FOUR WEEKS</u>. Please SELECT the appropriate number, using the following code:

0 - Not at all 1 - Slightly

2 - Moderately

3 - Quite a bit

4 - Extremely

	How much have you been bothered in the past 4 weeks?												How much have you been bothered in the past 4 weeks?						
	Symptom Problem	0	1	2	3	4			Symptom Problem	0	1	2	3	4					
21.	Chest pains	0	0	0	0	0		30.	Insomnia	0	0	0	0	0					
22.	Fever	0	0	0	0	0		31.	Depression	0	0	0	0	0					
23.	Nausea	0	0	0	0	0		32.	Headaches	0	0	0	0	0					
24.	Upset stomach or indigestion	0	0	0	0	0		33.	Breast sensitivity/tenderness	0	0	0	0	0					
25.	Vomiting	0	0	0	0	0		34.	General aches and pains	0	0	0	0	0					
26.	Intestinal gas (flatulence)	0	0	0	0	0		35.	Joint pains	0	0	0	0	0					
27.	Sinus problems	0	0	0	0	0		36.	Swelling of hands or feet	0	0	0	0	0					
28.	Coughing	0	0	0	0	0		37.	Muscle stiffness	0	0	0	0	0					
29.	Skin rash	0	0	0	0	0		38.	Early awakening	0	0	0	0	0					
	Signature of Person Completing Form																		

Page 2 of 2







Screening ID#	Acrostic	Date	of Interview	Staff ID #
		Month D	ay / Year	

CES-D

		• •
\/	10	IŤ.
v	13	I L.

O Randomization

O 6 Month Visit (Closeout)

For each of the following statements, please tell me if you felt that way: Rarely, or none of the time; some of the time; much of the time; or, most or all of the time

During the past week	Rarely or none of the time (< 1 day)	Some of the time (1-2 days)	Much of the time (3-4 days)	Most or all of the time (5-7 days)	Don't Know	Refused
I was bothered by things that usually don't bother me.	0	0	0	0	0	0
2. I did not feel like eating; my appetite was poor.	0	0	0	0	0	0
I felt that I could not shake off the blues even with the help of my family or friends.	0	0	.0	0	0	0
4. I felt that I was just as good as other people.	0	0	0	0	0	0
I had trouble keeping my mind on what I was doing.	0	0	0	0	0	0
6. I felt depressed.	0	0	0	0	0	0
7. I felt that everything I did was an effort.	0	0	0	0	0	0
8. I felt hopeful about the future.	0	0	0	0	0	0
9. I thought my life had been a failure.	0	0	0	0	0	0
10.I felt fearful.	0	0	0	0	0	0
11.My sleep was restless.	0	0	0	0	0	0
12.I was happy.	0	0	0	0	0	0
13.I talked less than usual.	0	0	0	0	0	0
14.I felt lonely.	0	0	0	0	0	0
15. People were unfriendly.	0	0	0	0	0	0
16.I enjoyed life.	0	0	0	0	0	0
17.I had crying spells.	0	0	0	0	0	0
18.I felt sad.	0	0	0	0	0	0
19.1 felt that people disliked me.	0	0	0	0	0	0
20.1 could not get going.	0	0	0	0	0	0



Screening ID#	Acrostic	Date of Inter	view	Staff ID#
		Month Day	Year	

24 HOUR URINE COLLECTION AND PROCESSING

Visit: O Randomization Visit

O 6 Month Visit (Closeout)

1.	Was the 24 hour urine collected? O Yes O No	
	Describe any problems:	
	Interviewer Note: Urine collection should be sent for processing to Core Lab.	
2.	Record the volume of urine (in CC): ccs	
3.	Record the creatinine results: mg/kg/day	
4.	Note location of banking:	

Interviewer Note: Samples should be banked at -20 C and sent to Dept. of Food Science and Nutrition, University of Minnesota, 1334 Eckles Ave., St. Paul, MN 55105 at closeout.





Screening ID #	Acrostic	Date of Interview	Staff ID#
·		Month Day Year	

NIPPLE ASPIRATION AND DUCTAL LAVAGE

Visit: OR	andomization O 6 Month Visit	t (Closeout)	
	A TITE IN TO THE		
	AFFIX LABEL		
RIGHT BREAST - Nipple Aspiration			
 Was Nipple Aspiration attem Was fluid elicited? 	pted?	<u></u>	O No
3. Identify each duct yeilding flu	uid?	O Yes	O No
4. Color of fluid? O Clear O White	O Yellow O Red O Green	O Brown O Blac	k O Other
RIGHT BREAST - Ductal Lavage			A
1. Was Ductal Lavage attempt	ed?	Yes O No	
2. Number of ducts with Nipple	e Aspirate Fluid?	01 02 03	
3. Duct ID#?			
4. Saline volume infused/return	ned in ml?	ml	mı

Page 1 of 2

Page Link #

PREVENT-Nipple Aspiration and Ductal lavage, 03/05/02



Screening ID # Acrostic	Date of Interview	Staff ID#

NIPPLE ASPIRATION AND **DUCTAL LAVAGE (cont.)**

LEFT BREAST - Nipple Aspiration						
1.	Was Nipple Aspiration attempted?	O Yes O No				
2.	Was fluid elicited?	O Yes O No				
3.	Identify each duct yeilding fluid?	O Yes O No				
4.	Color of fluid?					
	O Clear O White O Yellow O Red O Green O E	Brown O Black O Other				
LEFT	BREAST - Ductal Lavage					
1.	Was Ductal Lavage attempted? O Yes	s O No				
2.	Number of ducts with Nipple Aspirate Fluid? O1	02 03				
3.	Duct ID#?					
4.	Saline volume infused/returned in ml?	ml ml				



Screening ID#	Acrostic	Date of Interview	Staff ID#
		Month Day Year	

FINAL ELIGIBILITY

Eligibility Criteria: All answers to the following questions should be YES.

	Meets Eligit	Meets Eligibility Criteria		
1. Signed Consent Forms	O Yes	O No		
2. Pre-menopausal, not on hormones	O Yes	O No		
3. Mammogram >50% density	O Yes	O No		
4. Clinical labs within acceptable range	O Yes	O No		
5. Gail Risk >1.66 OR BRCA2 mutation	O Yes	O No		
6. History and Physical Exam (includes Clinical Breast Exam)	O Yes	O No		
7. Baseline urine and blood collection	O Yes	O No		
8. Ductal Lavage attempted (sample collected)	O Yes	O No		
9. Pregnancy test negative	O Yes	O No		
10. NOT had highly irregular menstrual cycle unless FSH, LH and estradiol are in the pre-menopausal normal range	O Yes	O No		
Agreed NOT to consume soy protein more than one time per week during the study period	O Yes	O No		
12. NOT had bilateral or unilateral prophylactic mastectomy	O Yes	O No		
13. NOT involved in another cancer prevention study	O Yes	O No		
14. NOT had active infections or inflammation in either breast	O Yes	O No		

Interviewer Note: If participant is eligible to continue, proceed to randomization.

A STATE OF THE STA	P Screening ID #	Acrostic Date of Interview	Staff ID #
	N T	RANDOMIZATION	
	Date Randomized:	Month Day Year	
	Randomization #:		
,			
The Inform	nation Contained In Th	nis Randomization Section Is Accur	ate And Complete.
		· · · · · · · · · · · · · · · · · · ·	
	Principal Investigator		Date



Screening ID#	Acrostic	polynomia Polynomia	Date of Inte	erview	Staff ID#
		Month /	Day	/ Year	

STUDY DRUG DISPENSATION

1.	1. A three month's supply of study pills/packets has been dispensed to participant?			
2.	Package #:			
3.	Was the 24 hour urine collection kit dispensed?		Yes O.No	



Screening ID #	Acrostic	Date of In	terview	Staff ID#
		Month Day	/ Year	

TELEPHONE FOLLOW-UP CHECKLIST

Visit: O 3 day O 30 day

	Ple	ase check if co	mpleted	
Checklist Items		No, participant refused	No, other reason	Comments
Compliance Assessment	0	0	0	

- O Participant contacted, follow-up completed
- O Participant contacted, left message
- O Refused to complete follow-up

0	Cal	l back
~	\ JC11	11001.5

Date:







Screening ID#	Acrostic	Date of Interview	Staff ID #
		Month Day	Year

TELEPHONE COMPLIANCE ASSESSMENT

		Visit: O 3 day O 3	0 day		
	1.	Are you currently taking the soy/placebo protein?	O Yes	O No	
	2.	Since our last contact, how many days have you NOT	taken your protein?		
	3.	Are you currently taking the tamoxifen/placebo pills?	O Yes	O No	
2	4.	Since our last contact, how many days have you NOT	<u>「</u> taken your pills?		



A CONTRACT WAS AND THE CONTRACT OF THE CONTRAC				
Screening ID#	Acrostic	Date of Inter	view	Staff ID#
		Month Day	Year	

3 MONTH FOLLOW-UP VISIT CHECKLIST

	Ple	ase check if co		
Checklist Items	Yes	No, participant refused	No, other reason	Comments
1. Adverse Event	0	0	0	·
2. Compliance	0	0	0	
3. Medication Update	0	0	0	
4. Symptom Checklist	0	0	0	
5. Dispense Therapy	0	0	0	

Participant Status

- O Eligible to continue, dispense pills/packets
- O Not eligible





Screening ID #	Acrostic		Date of Inter	view	Staff ID#
		Month /	Day /	Year	

MEDICATION INVENTORY FOLLOW-UP

	Visit:	O 3 Mo	nth Follo	w-up V	/isit O	6 Month	Follow	-up Vis	sit (Clos	eout)	
1. Examiner say:	Have yo	u taken									isit?
			O Yes			O No —	L.				
2. Examiner: Are criteria in the	any of to	he partion?			ations/su		_				sion
•			Q Ye	S		O No -	→ [Go to	questior	n 3.	*.
Record medications Listing" and if they previously recorded Please record by I	have not d and was	been red s stopped	corded at d/restarte	a prev	ious visit.	EXCER	NOITS	: If a m	edicatio	n has t	een.
A. Medication											
Reason for use											
Date Started	/	/			Date Stopped]/]/[
	· · · · · · · · · · · · · · · · · · ·	·			<u>.</u>	O On	going				
B. Medication											
Reason for use											
Date Started]/]/[Date Stoppe	d [/		1/		
						O On	going				
C. Medication											
Reason for use								·			
Date Started	/]/[Date Stoppe	d	7		7/[
						O On	going	<u> </u>	· · · · · · · · · · · · · · · · · · ·	- L	

Page 1 of 1





Screening ID # Acrostic	Date of Interview	Staff ID#

MEDICATION INVENTORY FOLLOW-UP (cont'd)

D. Medication	
Reason for use	
Date Started / Date Stopped	
	O Ongoing
E. Medication	
Reason for use	
Date Started / Date Stopped	/ / / /
	O Ongoing
F. Medication	
Reason for use	
Date Started / Date Stopped	/ / / /
	O Ongoing
G. Medication	
Reason for use	
Date / Date Stopped	
	O Ongoing
H. Medication	
Reason for use	
Date Started / Date Stopped	
	O Ongoing
3 Evenines Heathanathanatha	

3. Examiner: Has the participant stopped or changed the dose of any concomitant meds reported on previous visits?

O Yes

O No

Page Link #

Page 1 of 1

PREVENT-Medication Inventory Follow-up, 03/05/02





The state of the s	P
13/2	R E
1 Kasa	٧
>	E N
	T

Screening ID#	Acrostic	Date of Interview	Staff ID#
		Month Day Year	

SYMPTOM CHECKLIST

Visit: O Randomization O 3 Month Visit O 6 Month Visit (Closeout)

Dear Participant: Please fill out this form and return it to a PREVENT staff member. If you have any questions about how to answer the items on this form, please ask for help. All of the information collected on this form will be kept strictly confidential and will be used only for research purposes. If you feel uncomfortable about answering any of these questions, please leave the item blank. Your answers to these questions will not affect your continued participation in this study.

What was the date of the first day of your last menstrual period?	Month Day	Year
---	-----------	------

We are interested in knowing the extent to which you have been bothered by any of the following problems during the **PAST FOUR WEEKS**. Please SELECT the appropriate number, using the following code:

0 - Not at all 1 - Slightly

2 - Moderately

3 - Quite a bit

4 - Extremely

			ı be	nuc en b ast 4	oth	· ····		Hov ou t	beer		her	ed	
; <u> </u>	Symptom Problem	0	1	2	3	4		Symptom Problem	0	1	2	3	4
1.	Hot flashes	0	0	0	0	0	11.	Weight loss	0	0	0	0	0
2.	Night sweats	0	0	0	0	0	12.	Decreased appetite	0	0	0	0	0
3.	Cold sweats	0	0	0	0	0	13	Abdominal cramps	0	0	0	0	0
4.	Constipation	0	0	0	0	0	14.	Leg cramps	0	0	0	0	0
5.	Vaginal discharge	0	0	0	0	0	15.	Difficulty with bladder control (when laughing or crying)	0	0	0	0	0
6.	Vaginal bleeding or spotting	0	0	0	0	0	16.	Difficulty with bladder control (at other times)	0	0	0	σ	0
7.	Genital itching/irritation	0	0	0	0	0	17.	Weight gain	0	0	0	0	0
8.	Vaginal dryness	0	0	0	0	0	18.	Forgetfullness	0	0	0	0	0
9.	Pain with intercourse	0	0	0	0	0	19.	I felt that people disliked me.	0	0	0	0	0
10.	Dry mouth	0	0	0	0	0	20.	I could not get going.	0	0	0	0	0
	Signature of Person Completing Form												

Draft



Screening ID#	Acrostic	Date of Interview	Staff ID#

SYMPTOM CHECKLIST (cont'd)

We are interested in knowing the extent to which you have been bothered by any of the following problems during the <u>PAST FOUR WEEKS</u>. Please SELECT the appropriate number, using the following code:

0 - Not at all 1 - Slightly 2 - Moderately 3 - Quite a bit 4 - Extremely

		you	be		oth	ve ered eks?			How ou the	oeer		ther	ed
	Symptom Problem	0	1	2	3	4		Symptom Problem	0	1	2	3	4
21.	Chest pains	0	0	0	0	0	30.	Insomnia	0	0	0	0	0
22.	Fever	0	0	0	0	0	31.	Depression	0	0	0	0	0
23.	Nausea	0	0	0	0	0	32.	Headaches	0	0	0	0	0
24.	Upset stomach or indigestion	0	0	0	0	0	33,	Breast sensitivity/tenderness	0	0	0	0	0
25.	Vomiting	0	0	0	0	0	34	General aches and pains	0	0	0	0	0
3 .	Intestinal gas (flatulence)	0	0	0	0	0	35.	Joint pains	0	0	0	0	0
27.	Sinus problems	0	0	0	0	0	36	Swelling of hands or feet	0	0	0	0	0
28.	Coughing	0	0	0	0	0	37	Muscle stiffness	0	0	0	0	0
29.	Skin rash	0	0	0	0	0	38	Early awakening	0	0	0	0	0
											-		
								Signature of Person Completing	For	m			,





Screening ID#	Acrostic	Date of Interview	Staff ID#
		Month Day Year	

COMPLIANCE ASSESSMENT

Visit	: O 3 Month Follow-up Visit	O 6 Month Follow-up Visit (Closeout)
Note: The pa	rticipant should take todd	ny's dosage before this form is completed.
Number of (by pill cou	tablets remaining nt):	Number of packets remaining (by packet count):



Screening ID#	Acrostic		Date of Inter	view	Staff ID#
		Month /	Day /	Year	

STUDY DRUG DISPENSATION

1.	A three month's supply of study pills/packets has been dispensed to participa	int? O Yes O No
2.	Package #:	
3.	Was the 24 hour urine collection kit dispensed?	O Yes O No



Screening ID#	Acrostic		Date of Inter	view.	Staff ID#
		Month /	Day /	Year	

6 MONTH FOLLOW-UP VISIT CHECKLIST

·	Plea	se check if con		
Checklist Items	Yes	No, participant refused	No, other reason	Comments
1. Adverse Event	0	0	0	*
2. Compliance	0	. 0	0	
3. Medication Update	0	0	0	
4. Symptom Checklist	0	0	0	
5. CES-D	0	0	0	
6. Anthropometrics	0	0	0	
7. Vital Signs	0	0	0	
8. Blood Draw	0	0	0	
9. Physical Exam	0	0	0	
10. 24 Hour Urine Collection	0	0	0	
11. Mammogram	0	0	0	
12. Nipple Aspiration/Ductal Lavage	0	0	0	

, ,		A.		P	Sc	reen	ing l	D#.		Acı	osti				.	Date	e of l	nter	view				St	aff II) # (*		
		Jil The		K E V										Mon	/		Day]/		Y	ear						
				E				•	<u> </u>			D.	\ \ / T /	'D				T. T.	nr.				<u> </u>			_	
)	, ,	r T		Vi	sit:	0	3 M	onth					SE sit					ow-	up \	/isit	(Clo	sec	ut)		
An ad	verse	eve	nt (AE_{j}) is c	lefii	ned	as a	ny i	llne	ss, s	ign	or	sym	pton	ıs, o	r u	nfav	ora	ble	cha	nge	in c	linic	al s	tatu	S
that h			red —	or v	vors	ene	d af	ter s	tart	of t	rial	wh	ethe	2r 01	not	COT	rsid	erec	l rel	atea	l to	the	use	of te	st dr	ug.	T
	OVEF EVE																										
		•													İ]
NCI	COM	IMO	NT	OXI	CIT	Y G	RAI	DE:	01	- N	lild	0	2 -	Mod	dera	te	03	3 - 8	Seve	ere	0	4 -	_ife-	thre	ater	nino	」
									SE	ERIC	DUS		0 Y		0								ı				,
AE RE	POR	T D	ATE	(m	m/d	d/yy	/):				/			/							121				t :		
DATE	OF C	NS	ET (mm	√dd.	/уу)	:	٠ [/			1												÷	
DATE	STO	PPE	1) D	nm	/dd/	уу):		Ī			1			1						00	Con	tinui	ing				
PATTI	ERN:		O E	Ever	y do	se	Q	Inte	ermi	tten	it (C	onti	า ทบด	us	0	Onc	<u> </u>	O V	lot a	anni	icat	ماد				
STUD	אט א				•								J. 7.1.		40		9110	•		100	, pp	ioai					
								سا م	•		4		-•-•			٥.						B.J.					: · ·
No																Stu	ay c	irug	dis	con	tınu	ed*	•				
OTHE	R AC	TIO	N T	AKI	EN E	BEC	AUS	SE C)FT	HIS	AE	:	0	Ye	s () N	0										
IF YES	<u>S, PL</u>	EAS	E S	PE	CIFY	_																					
																											•
											,									<u> </u>					\neg		
	+																		-								
	-										/		-	-							_	_					
OUTTO					<u> </u>		<u> </u>	1			<u> </u>			<u> </u>								<u> </u>	<u> </u>				
OUTC		•		ده اه	مادد	<u> </u>	7						-1 -1	ee													
O Rec RELA							1ec	ove	rea v	WITH	res	siau	aı e	пест	S (onti	null	ng	O	-ata	11 "	0	Unk	now	n	
							_					,															
O No								OF																			
	rious : partici	In	re-th	reat	ening	7, co	ngei	nital :	anon	naly,	, car	cer	or or	verdo	ose.	Fill (Out 5	Seric	ous A	ngati Idve	ion o rse L	f ho. Even	spita t For	lizati m.	on,		
																								-	*********	-	

Principal Investigator's Signature Date

				200968	Company letters when	138666981386	e Jaarsus Stude	- Lucasea	ASS - 2 No.	Warran Bayan	v v. 40														
,			§ P	150,000,00	Scree	ning l	D# :		Ac	rosti	C.				Dat	e of	inter	view	Æ,			Š	taff I	D#	
		7	R E									$\ \ \ $			<i>,</i> [T	7/						T	$\overline{\Box}$	
	,	La:	V						l		<u> </u>]	Mon	⊥ ′ th	L_	Day	」′	<u>L</u>	Y	ear		L			'
		у .	E	. i						-	<u> </u>	X 7 W					7 7 7				·				
			N T		• •	<i>.</i>	_					VE								,					
		<i>j</i>				isit:														-		•		,	
aa ut h	ivers as a	e ever opear	ıt (A ed o	(E) is	s defi rsen	ined ed at	as a Hor	ny i	llne	SS, S	sign	or	sym _i	pton	ns, c	or u	nfa	vora	ble	cha	nge	in e	clini	cal s	tatu
	OVEF			. <i>m</i> 0					\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	T illi	T	leine	7 01	To	1 601	ista	erec	l rei	aiec		tne	use	oj te	est a	rug. T
	EVE					+-	+-	-	-	-	-	-	-	-	-	-	-			-		\bot		1_	
CI	COV	MON	I TC	XIC	ITY C	3RA	DE:	O 1	- N	lild	0	2 -	Mod	dera	te	03	3 - 8	Seve	ere	0	4 -	Life	-thre	ate	ning
					· · ·			SE	RIC	DUS	<u>:</u>	<u> </u>	es*	0	No						·				
RE	POF	T DA	TE ((mm	/dd/y	'y):				1			/												
rF	OF (ONSE	T (n	nm/d	ld/\n/	۸.	[1			,] 					.*		
	0. (. (11		icu y y	<i>)</i> -	ļ			/			/												
Έ	STO	PPE) (m	m/de	(yy/c	:				/			/						0	Con	tinu	ing			
TI	ERN:	. (DΕν	/erv	dose	. C	inte	ermi	tten	it (onti	nuo:	118		 Эпс	۵	Ο <i>Ι</i> ,	lot s	anni	lical	olo			
ID.	V DE									,		01111	· ·uo	uo		J110	C	O 1.	101 6	zpp.	licai	JIC			
		UG D																							
0	O F	Reduc	ed (dose	; O	Dos	e In	terri	uptio	on (Res	start	ed)	0	Stu	dy c	drug	dis	con	tinu	ed*	*			-
HE	R AC	MOITS	I TA	KEN	BEC	CAUS	SE C)FT	HIS	AE	:	0	Yes	s (N C	0									
ÆS	3, PL	EASE	SP	PECII	<u>=Y</u>		**																		
				T	T	T	,											<u> </u>		Γ		Τ	Т		\neg
-	+-		+	_	+-	+						┼─										-	-	\vdash	\dashv
	+-	\vdash	-		 	+						\vdash	ļ					 		ļ	-	┞	ļ	\square	
												ļ		`											
							ł																		
<u>TC</u>	OME			٠.						•					·				·	<u> </u>				<u> </u>	
lec	over	ed co	mpl	etely	/ 0	Rec	over	ed v	with	res	idu	al el	fect	s	o c	onti	nuii	ng	O F	=ata	al*	0	Unk	now	/n
		TO S																_							
		Jnlike				-	0.5) Proh	ahl	a 4	O D	afin	ito												
		= Dea life	-tnre	ateni	ing, co	ongei	nital i	anon	naly.	can	cer	or ou	rerdc	se.	Fill (Out S	Seric	us A	igati Idve	on o	f ho. Even	spita t Fo	ilizati rm	on,	
*If p	oartic	ipant d	isco	ntinu	ed dri	ug, c	omp	lete :	Stud	y Dr	ug L	Disco	ntinu	ıatio	n Vis	it Fo	orms								
-		-			,																			Jeneti Laure	
	*	Drie	ncin	al Inve	estiga	toric	Cia	ate			,														
		7111	υIμά	u uve	;งแga	IUI'S	əıgn	acure	7								Da	te							

PREVENT-Adverse Event 03/05/02

Date



£*. *	The state of the s		P	્ર Sc	reen	ing l	D#		Ac	rosti	c 🎺		149		Da	te of	Inte	rviev	y (Staff	ID#		
	Sortiff Sortiff	.	K E V E										Mon	th	<u> </u>	Day]/	· [_	Y	ear ear						
			N T				,	-						SE												
An adver	se eve ippea	ent (red	or v) is o	defi ene	ned d af	as a fter s	iny i start	llne of	ess, tria	sign l wh	or eth	sym _i er oi	pton r noi	ns, t co	or u nsia	nfa lere	vord d re	ible late	cha d to	nge the	in use	clini of t	ical . est a	stat !rug	us
ADVE																•							Ĭ			
NCI CO	MMO	N T	OXI	ICIT	ΥG	RAI	DE:										3 - \$	Sev	ere	0	4 -	Life	-thr	eate	nin	g
					-			SI	ERIC	OUS	S:	O Y	es*		No			·				·				
AE REPO	RT D	ATE	(m	m/d	d/yy	/):				/			/													
DATE OF	ONS	ET ((mn	n/dd	/yy)	:				/			/												,	
DATE ST	OPPE	t) Œ	mm	/dd/	уу):					/			/						0	Con	tinu	ing				
PATTERN	l:	O E	Ever	y do	ose	0	Inte	ermi	tter	nt (o 0	onti	nuo	us	0	Onc	e	01	Not a	appl	ical	ble				
STUDY D	RUG	DO:	SE (CHA	NG	E														. ,						
O No O	Redu	icec	d do	se	0	– Dos	e In	terr	upti	on ((Re	start	ed)	0	Stu	ıdy (drug	g dis	con	itinu	ed*	*				
OTHER A													Yes) N											
IF YES, P	LEAS	SE S	PE	CIFY	<u></u>																					
																							T] .
																		 	<u> </u>				<u> </u>	-		
				·							-							<u> </u>								
														·									-			1
OUTCOM	E								·	1	1	.1	1	لـــــا		I	1	1	1	<u> </u>	<u>. </u>		<u>.l</u>	<u>i</u>		j
O Recove	red c	om	olet	ely	O F	Rec	ove	red v	with	res	sidu	al e	fect	s (o c	ont	inui	ng	0	Fata	ıl*	0	Unl	cnov	/n	
RELATE	OTO	STL	JDY	DR	<u>UG</u>				٠																	
0 No 0	Unlik	ely	0	Pos	ssib	le	O F	Prob	abl	е	O D	efin	ite						:		**					
* Serious	In	re-tni	reate	ening	7, co	nger	nital .	anon	nalv.	. car	icer .	or or	rerda	se.	Fill (Out :	Serio	DUS A	ngati Idve	ion o rse E	f ho ven	spita t Fo	ilizat rm.	ion,		·

Draft

Date

Principal Investigator's Signature

Page 1 of 1

P Screening ID# Acrost E V E N T DRUC	Date of Interview Staff ID #
 Record the last day the participant took the study tablets/packets: 	Month Day Year
	It decided to stop taking the study tablets/packets? ory and one sub-categoryif appropriate.)
O Upset stomach O Nau	ısea
O Diarrhea O Bloa	ating
O Hot flashes O Oth	er side effects (please specify):
O Participant decision	
O Physician's advice	O Doesn't like taking medication on a daily basis
O Family member advice	O Illness/health problem (non-AE)
O Does not want to be on placebo	O Other side (please specify):
O Other (Please specify):	

Appendix B

Informational Tools



Soy / Tamoxifen Study Visit Outline

Questions ? Contact Nicole (415) 353-9739 nicole.guthrie@ucsfmedctr.org

Please remember all clinic visits must take place between days 7-13 of your menstrual cycle

My target window for visits is days _____ to ____ of the month

Screening Visit (2 hours)

- Sign study consent form
- Mammogram in the MammoVan (parking lot behind Cancer Center)
- Physical exam / Medical History at Breast Care Center (2nd floor)
- Provision of a 1 month supply of Run-in study protein and pills
- Blood draw at Phlebotomy lab (1st floor)

1 month

Randomization Visit (2 hours)

• In the clinic on the 2nd floor

Turn in 24 hour urine sample Collection of any remaining Run-in study protein and pills Inventory of current Medication / Review of any symptoms Nipple aspiration / Ductal Lavage

Randomization and provision of study protein and pills

Telephone Follow-up (15 minutes each)

They will take place approximately
 3 days after Randomization visit
 30 days after Randomization visit

3 months

3 Month Visit (45 minutes)

A visit with Nicole (6th floor, elevators past the gift shop)
 Update forms (bring any new medications since Randomization visit)
 Pick up a new supply of study protein and pills (Pharmacy 5th floor)

3 months

Final Visit, 6 month follow-up (2 hours)

- Blood draw at Phlebotomy lab (1st floor)
- Mammogram in the MammoVan
- In the Breast Care Clinic on the 2nd floor Turn in 24 hour urine sample Physical exam / medical history update Nipple aspiration / Ductal Lavage

THANK YOU for your participation in this important research study



Dietary Guidelines

Please limit your consumption of soy foods through out the entire study Total consumption of soy foods should be limited to 1 serving a week through out the study

Listed below are common soy foods. Please, be aware that many prepared and processed foods also contain soy and <u>not all of these foods are listed here</u>. If an item has soy or textured vegetable protein listed in the first 2 ingredients, please limit the frequency that it is consumed.

tofu tempeh soy milk okara edamame/ soy beans

soy nuts soy cheese soy yogurt Balance bars Luna bars Smart Dogs

Morning Star: Grillers, Chik Patties, Corn Dogs

Boca Burgers and meat replacements

Veat, all products

Natural Touch Garden Veggie Pattie

If you are looking for a <u>soy free</u> vegetable patty try

Amy's California Veggie Burger Gardenburger all flavors except the Hamburger Style

■ The following items **should not be used** through out the length of the study. Please be aware that they may be added to 'energy bars' and some specialty cereals and beverages.

Red Clover:

Trifolium pratense, meadow clover, purple clover, trefoil

Black Cohosh:

Cimicifuga racemosa, baneberry, black snakeroot, bugbane, squaw

root, rattle root

Chaste tree:

Vitex angus-castus, Chaste berry

■ If you have any questions please contact Nicole by phone at (415) 353-9739 or email at nicole.guthrie@ucsfmedctr.org

University of California San Francisco



Comprehensive **Cancer Center**

Carol Franc Buck **Breast Care Center** A Program of the National Center of Excellence In Women's Health

1600 Divisadero Street 2nd Floor San Francisco, CA 94115 For non-express mail use: Box 1710 San Francisco, CA 94143-1710

Tel: 415/353-7070 oncology Tel: 415/353-7111 surgery

Fax: 415/353-7021

		* 4. * 4.		a.
·				, 2002
•			,	
Dear Dr:		•	-	
Your patient,		, date of birth _		, has
enrolled in the PREVENT study at the	UCSF Brea	st Care Center.		•
The study is being conducted by Jeffic and associates from the University of is to investigate the effects of dietary and urinary estrogen metabolites, in conducted by Jeffic and associates from the University of its to investigate the effects of dietary and urinary estrogen metabolites, in conducted by Jeffic and associates from the University of its total associates fro	California S y soy on bro	an Francisco. The east density, nippl	purpose e aspira	e of the study
The study period is a total of 6 mon letter. Your patient has agreed for the hormonal or selective estrogen recept	e length of th	ne study period to	not use	

As part of the study the patient will receive 2 mammograms, one at the start of the study and another at the end of the 6-month period. The results of these measurements, as well as all other tests performed will be available on the patient's request.

If you have any questions or concerns about the participation of your patient in this research project, please feel free to call.

Sincerely;

Nicole Guthrie, MS **Study Coordinator** (415) 353-9739

